New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
04:55 EDTEBIO, EBIO, EBIO, EBIO, SURG, SURG, SURG, SURG, DNA, DNA, DNA, DNA, XOMA, XOMA, XOMA, XOMA, SQNM, SQNM, SQNM, SQNM, REGN, REGN, REGN, REGN, MRK, MRK, MRK, MRK, CAJ, CAJ, CAJ, CAJ, AGN, AGN, AGN, AGN, AGTC, AGTC, AGTC, AGTC, VRX, VRX, VRX, VRXAssociation for Research in Vision & Ophthalmology holds annual meeting
2014 Annual Meeting of ARVO is being held in Orlando, Florida on May 4-8.
News For EBIO;AGTC;AGN;CAJ;MRK;REGN;SQNM;XOMA;DNA;SURG;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
14:48 EDTREGNRegeneron primary driver remains Praluent, says Piper Jaffray
Piper Jaffray noted that Regeneron (REGN) shares are at all-time highs after the company and partner Sanofi reported Phase IIb data on Dupilumab and Phase III data on Sarilumab. However, the firm believes the primary driver for Regeneron remains Praluent and firm expects launch costs to outstrip sales growth. Piper acknowledges Regeneron has "one of the richest pipelines in all of biotech," but it sees risk around Amgen's (AMGN) patent suit and keeps its Neutral rating and $484 price target on the stock.
09:31 EDTCAJCanon downgraded to Sell from Hold at Deutsche Bank
05:15 EDTREGNRegeneron, Sanofi announce positive topline results from sarilumab Phase 3 study
Subscribe for More Information
May 20, 2015
08:53 EDTREGNRegeneron price target raised to $560 from $500 at Argus
Argus increased its price target on Regeneron as the firm notes that the company has had positive pipeline and earnings news over the past year, and has increased its sales outlook. Argus thinks the company has a strong pipeline and keeps a Buy rating on the shares.
07:38 EDTREGNRegeneron price target raised to $600 from $525 at Canaccord
Canaccord raised its price target on Regeneron to $600 from $525 following positive top-line data for its Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma. The firm sees the data as significant, as it reinforces the role of dupilumab and increases the potential future revenue stream for the company. Canaccord reiterated its Buy rating on Regeneron shares.
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 19, 2015
08:12 EDTEBIOEleven Biotherapeutics price target lowered to $6 from $23 at Leerink
Subscribe for More Information
07:28 EDTMRKUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:55 EDTMRKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
16:21 EDTEBIOOn The Fly: Top stock stories for Monday
Stocks on Wall Street advanced in Monday trading, sending the Dow Jones Industrial Average and the S&P 500 to new all-time closing highs. The early part of the day saw the market move in a narrow range, but by early afternoon the market punched through its upper range and moved to session highs. The market drifted throughout the afternoon as the news flow was quiet and the trading volume remained light. ECONOMIC EVENTS: In the U.S., the National Association of Home Builders’ confidence index fell 2 points to a reading of 54 in May, missing expectations for a 1 point increase to a reading of 57. COMPANY NEWS: Shares of Apple (AAPL) advanced $1.47, or 1.14%, to $130.24 after noted investor Carl Icahn stated in an open letter to the company's CEO that he thinks other investors, analysts and the news media continue to misunderstand Apple and that its stock is "worth $240 today." Icahn urged Apple CEO Tim Cook to take advantage by launching a "much larger buyback" of the iPhone maker's shares. Separately, FBR Capital analysts Daniel Ives and James Moore wrote this morning in a note to investors that the Street is still underestimating Apple's growth outlook in China. The analysts believe that Apple's China revenue will exceed its revenue from the Americas in fiscal 2017... Endo International (ENDP) slid $4.53, or 5.31%, to $80.82 after the company agreed to pay $8B for privately held Par Pharmaceutical, which will roughly double Endo’s generics revenue and place its generics business among the top five as measured by U.S. sales. MAJOR MOVERS: Among the notable gainers was Ann Inc. (ANN), which surged $7.69, or 19.87%, to $46.40 after agreeing to be acquired by Ascena Retail Group (ASNA) for about $2.15B in cash and stock. Ascena, which agreed to pay $37.34 in cash and 0.68 of a share of its own common stock in exchange for each share of the parent of the Ann Taylor brand, slipped 14c, or 0.99%, to $14.07 after announcing the deal. Also higher was Achillion (ACHN), which rose $1.41, or 14.79%, to $10.98 after the company cancelled its presentation at the UBS Global Healthcare Conference. Conference cancellations often generate speculation as to whether a company is engaged in merger or acquisition talks. Among the noteworthy losers was Eleven Biotherapeutics (EBIO), which dropped $8.29, or 69.26%, to $3.68 after announcing the company’s Phase 3 study of its lead drug candidate, EBI-005, in moderate to severe dry eye disease did not meet either of its two co-primary endpoints. Also lower were shares of Weibo (WB), which fell 87c, or 5.24%, to $15.73 after the shares were downgraded to Hold from Buy at Summit Research. INDEXES: The Dow rose 26.32, or 0.14%, to 18,298.88, the Nasdaq gained 30.15, or 0.6%, to 5,078.44, and the S&P 500 added 6.47, or 0.3%, to 2,129.20.
12:34 EDTREGNRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
09:25 EDTEBIOOn The Fly: Pre-market Movers
Subscribe for More Information
07:33 EDTEBIOEleven Biotherapeutics resumes trading, shares down 70.8% in pre-market trading
Subscribe for More Information
07:30 EDTEBIOEleven Biotherapeutics to host conference call
Subscribe for More Information
07:15 EDTEBIOEleven Biotherapeutics to resume trading at 7:30 am ET
Subscribe for More Information
07:03 EDTEBIOEleven Biotherapeutics will not initiate second Phase 2 study of EBI-005
Subscribe for More Information
07:02 EDTEBIOEleven Biotherapeutics says Phase 3 EBI-005 study did not meet primary endpoints
Subscribe for More Information
07:00 EDTEBIOEleven Biotherapeutics trading halted, news pending
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use